Gd(iii)-Pt(iv) theranostic contrast agents for tandem MR imaging and chemotherapy

被引:31
作者
Adams, Casey J. [1 ,2 ,3 ,4 ]
Meade, Thomas J. [1 ,2 ,3 ,4 ]
机构
[1] Northwestern Univ, Dept Chem, Evanston, IL 60208 USA
[2] Northwestern Univ, Dept Mol Biosci, Evanston, IL 60208 USA
[3] Northwestern Univ, Dept Neurobiol, Evanston, IL 60208 USA
[4] Northwestern Univ, Dept Radiol, Evanston, IL 60208 USA
关键词
CISPLATIN-RESISTANCE; PLATINUM(IV) PRODRUG; COMPLEXES; DELIVERY; DRUGS; DNA;
D O I
10.1039/c9sc05937g
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Pt(iv) prodrugs have emerged as versatile therapeutics for addressing issues regarding off-target toxicity and the chemoresistance of classic Pt(ii) drugs such as cisplatin and carboplatin. There is significant potential for Pt(iv) complexes to be used as theranostic agents, yet there are currently no reported examples of Gd(iii)-Pt(iv) agents for simultaneous MR imaging and chemotherapy. Here we report the synthesis, characterization, and in vitro efficacy of two Gd(iii)-Pt(iv) agents, GP1 and GP2. Both agents are water soluble and stable under extracellularly relevant conditions but are reduced under intracellular conditions. Both are cytotoxic in multiple cancer cell lines, cell permeable, and significantly enhance the T-1-weighted MR contrast of multiple cell lines. Thus, GP1 and GP2 are promising agents for tandem MR imaging and chemotherapy and provide a versatile platform through which future Gd(iii)-Pt(iv) agents can be developed.
引用
收藏
页码:2524 / 2530
页数:7
相关论文
共 45 条
  • [1] Drug Delivery Strategies for Platinum-Based Chemotherapy
    Browning, Richard J.
    Reardon, Philip James Thomas
    Parhizkar, Maryam
    Pedley, R. Barbara
    Edirisinghe, Mohan
    Knowles, Jonathan C.
    Stride, Eleanor
    [J]. ACS NANO, 2017, 11 (09) : 8560 - 8578
  • [2] A cisplatin-based platinum(IV) prodrug containing a glutathione s-transferase inhibitor to reverse cisplatin-resistance in non-small cell lung cancer
    Chen, Hong
    Wang, Xinyi
    Gou, Shaohua
    [J]. JOURNAL OF INORGANIC BIOCHEMISTRY, 2019, 193 : 133 - 142
  • [3] Lysosomal calcium homeostasis defects, not proton pump defects, cause endo-lysosomal dysfunction in PSEN-deficient cells
    Coen, Katrijn
    Flannagan, Ronald S.
    Baron, Szilvia
    Carraro-Lacroix, Luciene R.
    Wang, Dong
    Vermeire, Wendy
    Michiels, Christine
    Munck, Sebastian
    Baert, Veerle
    Sugita, Shuzo
    Wuytack, Frank
    Hiesinger, Peter Robin
    Grinstein, Sergio
    Annaert, Wim
    [J]. JOURNAL OF CELL BIOLOGY, 2012, 198 (01) : 23 - 35
  • [4] Cisplatin in cancer therapy: Molecular mechanisms of action
    Dasari, Shaloam
    Tchounwou, Paul Bernard
    [J]. EUROPEAN JOURNAL OF PHARMACOLOGY, 2014, 740 : 364 - 378
  • [5] Particular aspects of platinum compounds used at present in cancer treatment
    Desoize, B
    Madoulet, C
    [J]. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2002, 42 (03) : 317 - 325
  • [6] Multi-platinum anti-cancer agents. Substitution-inert compounds for tumor selectivity and new targets
    Farrell, N. P.
    [J]. CHEMICAL SOCIETY REVIEWS, 2015, 44 (24) : 8773 - 8785
  • [7] Glutathione: Overview of its protective roles, measurement, and biosynthesis
    Forman, Henry Jay
    Zhang, Hongqiao
    Rinna, Alessandra
    [J]. MOLECULAR ASPECTS OF MEDICINE, 2009, 30 (1-2) : 1 - 12
  • [8] Systems biology of cisplatin resistance: past, present and future
    Galluzzi, L.
    Vitale, I.
    Michels, J.
    Brenner, C.
    Szabadkai, G.
    Harel-Bellan, A.
    Castedo, M.
    Kroemer, G.
    [J]. CELL DEATH & DISEASE, 2014, 5 : e1257 - e1257
  • [9] Clinical perspectives on platinum resistance
    Giaccone, G
    [J]. DRUGS, 2000, 59 (Suppl 4) : 9 - 17
  • [10] The molecular perspective: Cisplatin
    Goodsell, David S.
    [J]. STEM CELLS, 2006, 24 (03) : 514 - 515